In mouse models of AD, intraperitoneal treatment of an IL-1 receptor-blocking antibody has also shown potential for improving cognition and reducing tau pathology, but additional clinical trials are required to determine the antibody’s safety and effectiveness in people [160]. The gene discussed is MAPT; the disease is Alzheimer disease.